About the Authors

Soizic Lecocq

Roles Investigation

Affiliation NeoNeuro SAS, Paris, France

Katia Spinella

Roles Investigation, Writing – original draft

Affiliation NeoNeuro SAS, Paris, France

Bruno Dubois

Roles Supervision

Affiliations Centre des Maladies Cognitives et Comportementales (IM2A), Pavillon François Lhermitte, Hôpital University of Pitié Salpêtrière, Paris France, Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié Salpêtrière, Paris, France, UMR-S975, École des Neurosciences, Paris, France, Université Pierre et Marie Curie-Paris 6, Paris, France, AP-HP, Paris, France

Simone Lista

Roles Supervision

Affiliations Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié Salpêtrière, Paris, France, Université Pierre et Marie Curie-Paris 6, Paris, France, AXA Research Fund & UPMC Chair, Sorbonne Universités, Paris, France, Inserm, Paris, France, CNRS, Paris, France, Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Paris, France

Harald Hampel

Roles Supervision

Affiliations Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié Salpêtrière, Paris, France, Université Pierre et Marie Curie-Paris 6, Paris, France, AXA Research Fund & UPMC Chair, Sorbonne Universités, Paris, France, Inserm, Paris, France, CNRS, Paris, France, Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Paris, France

Gregory Penner

Roles Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Writing – original draft, Writing – review & editing

gpenner@neoneuro-aptamers.com

Affiliation NeoNeuro SAS, Paris, France

Competing Interests

NeoNeuro SAS is a private for-profit company. The author, Soizic Lecocq declares that she has a competing interest in the publication of this manuscript by virtue of her continued employment at the company, and that the publication of this manuscript would benefit the company. The author, Katia Spinella left the company prior to the submission of this manuscript and therefore has no competing interest. The author, Gregory Penner is a co-owner of NeoVentures Biotechnology Inc., a company that is the majority owner of NeoNeuro SAS. As such, Dr. Penner declares that he has a competing interest in the publication of this manuscript given that he would benefit by financial gain on the part of NeoNeuro. At this time, Dr. Penner remains unpaid by NeoNeuro. NeoNeuro has filed a U.S. provisional patent (Aptamers as biomarkers, US 624606887) regarding the Aptamarker concept. NeoVentures Biotechnology has filed FRELEX patent (Method for the selection of aptamers for unbound targets, WO 2017035666 A1). These declarations of competing interest and the disclosure of the patent application do not in any way restrict the full and open peer review of the manuscript nor the sharing of all data reported in the manuscript. Dr. Harald Hampel declares no conflict of interest with the content of the present manuscript. He serves as Senior Associate Editor for the Journal Alzheimer’s & Dementia; he has been a scientific consultant and/or speaker and/or attended scientific advisory boards of Axovant, Anavex, Eli Lilly and company, GE Healthcare, Cytox Ltd, Jung Diagnostics GmbH, Roche, Biogen Idec, Takeda-Zinfandel, Oryzon Genomics, Qynapse; and he receives research support from the Association for Alzheimer Research (Paris), Pierre and Marie Curie University (Paris), Pfizer & Avid (paid to institution); and he has patents, but receives no royalties. Dr. Simone Lista received lecture honoraria from Roche.